Pancreatic Cancer Research

Clinical trialPhase 2Completed

Durvalumab in HIV-1 Patients With Solid Tumors

A Phase II Exploratory Study of Durvalumab (MEDI4736) in HIV-1 Patients With Advanced Solid Tumors.

Outcome
Results posted; single-arm, no comparison
Phase
Phase 2
Status
Completed
Study type
Interventional
Start
24 April 2017
Ended
22 March 2022
Enrollment
20 participants
Sites
8
Primary outcomes
Best Response During the Treatment Period
Sponsor type
Academic / other
Results posted
24 June 2024
Last update
24 June 2024

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 24 June 2024
Primary outcome
Best Response During the Treatment PeriodComplete Response: Experimental Arm: 1, n = 20Partial Response: Experimental Arm: 3, n = 20Stable disease: Experimental Arm: 5, n = 20Progression Disease: Experimental Arm: 7, n = 20Not Evaluated: Experimental Arm: 4, n = 20Values: participantsTime frame: From the first dose until last follow up, assessed up to 24 monthNo analysis posted for this outcome (outcome 1)
Participants
Experimental Arm: 20 started, 20 completed
Serious adverse events
Experimental Arm: 11 of 20Participants with at least one serious adverse event, of those at risk, as posted
10 secondary outcomes, the first 8 shown
Duration of Response Global
Anal: Experimental Arm 3.78 (0), n=1 [median Months, Standard Deviation] (first of 3 rows)
PFS · Progression Free Survival (PFS)
Experimental Arm 2.5 (1.4 to 5.9), n=20 [median Months, 95% Confidence Interval]
Duration of Response- Dolutegravir/ no Dolutegravir
Dolutegravir: Experimental Arm 27.4 (3.7 to 40), n=5 [median Month, 95% Confidence Interval] (first of 2 rows)
Duration of Response by Treatment With INSTIs or no INSTIs
Integrase Inhibitors: Experimental Arm 11.32 (3.71 to 27.40), n=6 [median Month, 95% Confidence Interval] (first of 2 rows)
OS · OS Analysis by PD-L1
PDL-1 negative: Experimental Arm 7.4 (1.2 to 16.3), n=11 [median Months, 95% Confidence Interval] (first of 2 rows)
OS · OS Analysis by Integrase Inhibitors
Integrase Inhibitors: Experimental Arm 11.5 (4.8 to 18.8), n=14 [median Months, 95% Confidence Interval] (first of 2 rows)
OS · OS Analysis by Dolutegravir
Dolutegravir: Experimental Arm 12.8 (1.0 to 18.8), n=10 [median Month, 95% Confidence Interval] (first of 2 rows)
PFS · PFS Analysis by PD-L1
Negative PDL-1: Experimental Arm 2.3 (1.2 to 6.2), n=11 [median Month, 95% Confidence Interval] (first of 2 rows)

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The proposal is a phase II clinical study designed to assess the feasibility of durvalumab (MEDI4736) in HIV-1-infected individuals with solid tumors. Additionally, to obtain data that lets understand the possible benefit of this treatment in cancer patients and HIV infection, exploring if activity of durvalumab (MEDI4736) could be higher in cancer that has been produced at least in part due to the chronic immunosupression. Simultaneously, it will allow us to investigate the effect of disrupting this immunoregulatory pathway might have in reversing cancer pathways and HIV-specific T-cell function during persistent chronic HIV infection in humans.

Detailed description public domain (ClinicalTrials.gov)

PD-1/ PD-L1 coinhibitory pathway plays a significant role in the regulation of the immune response in both chronic infectious diseases and cancer. Preclinical and animal data support the safety and promising activity of anti-PD-1 antibody in HIV-1 infection. Demonstrated anticancer activity and safety profile of durvalumab (MEDI4736) in cancer clinical trials. Unlikely drug interactions of durvalumab (MEDI4736) and antiretroviral treatments. The proposal is a phase II clinical study designed to assess the feasibility of durvalumab (MEDI4736) in HIV-1-infected individuals with solid tumors. Additionally, to obtain data that lets understand the possible benefit of this treatment in cancer patients and HIV infection, exploring if activity of durvalumab (MEDI4736) could be higher in cancer that has been produced at least in part due to the chronic immunosupression. Simultaneously, it will allow us to investigate the effect of disrupting this immunoregulatory pathway might have in reversing cancer pathways and HIV-specific T-cell function during persistent chronic HIV infection in humans. In this regard, our hypothesis is: HIV patients with cancer have a similar outcome in terms of tolerability when treated with durvalumab (MEDI4736) monotherapy at the recommended dose than non HIV infected patients.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Best Response During the Treatment Period [From the first dose until last follow up, assessed up to 24 month]. Number, participants. Complete Response: Experimental Arm (n=20): 1. Partial Response: Experimental Arm (n=20): 3. Stable disease: Experimental Arm (n=20): 5. Progression Disease: Experimental Arm (n=20): 7. Not Evaluated: Experimental Arm (n=20): 4.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Duration of Response Global [From the time from first response evaluation to progression or death, assessed up to 24 months.]. Median, Months (Standard Deviation). Anal: Experimental Arm (n=9): 3.78 (0). Melanoma: Experimental Arm (n=9): 7.39 (0). NSCLC: Experimental Arm (n=9): 3.7 (1.2).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Progression Free Survival (PFS) [From the date of randomization until end of follow up, assessed up to 24 months.]. Median, Months (95% Confidence Interval). Experimental Arm (n=20): 2.5 (1.4 to 5.9).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Duration of Response- Dolutegravir/ no Dolutegravir [From the date of first response until progression or death, assessed up to 24 months.]. Median, Month (95% Confidence Interval). Dolutegravir: Experimental Arm (n=9): 27.4 (3.7 to 40). No Dolutegravir: Experimental Arm (n=9): 2.8 (1.2 to 3.8).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Duration of Response by Treatment With INSTIs or no INSTIs [From the date of the first response until progression or death, assessed up to 24 months]. Median, Month (95% Confidence Interval). Integrase Inhibitors: Experimental Arm (n=9): 11.32 (3.71 to 27.40). No Integrase Inhibitors: Experimental Arm (n=9): 2.10 (1.22 to 3.78).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

OS Analysis by PD-L1 [OS is defined as the time from the inclusion date to the death, due to any cause. A patient who does not dies, is censored up to 24 months]. Median, Months (95% Confidence Interval). PDL-1 negative: Experimental Arm (n=15): 7.4 (1.2 to 16.3). PDL-1 positive: Experimental Arm (n=15): 18.9 (17.0 to 25).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

OS Analysis by Integrase Inhibitors [From the time from the inclusion date to the death, due to any cause. A patient who does not dies, is censored up to 24 months]. Median, Months (95% Confidence Interval). Integrase Inhibitors: Experimental Arm (n=20): 11.5 (4.8 to 18.8). No Integrase Inhibitors: Experimental Arm (n=20): 6.0 (0.4 to 33.3).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

OS Analysis by Dolutegravir [From the time from the inclusion date to the death, due to any cause. A patient who does not dies, is censored up to 24 months]. Median, Month (95% Confidence Interval). Dolutegravir: Experimental Arm (n=20): 12.8 (1.0 to 18.8). No Dolutegravir: Experimental Arm (n=20): 8.4 (0.4 to 19.1).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

PFS Analysis by PD-L1 [PFS is defined as the time from the inclusion date to the progression or death, due to any cause, up to 24 months patient who does not progresses neither dies, is censored at the last tumor evaluation where no progression is detected.]. Median, Month (95% Confidence Interval). Negative PDL-1: Experimental Arm (n=15): 2.3 (1.2 to 6.2). Positive PDL-1: Experimental Arm (n=15): 5.7 (4.1 to 17.0).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

PFS Analysis by Integrase Inhibitors [From the inclusion date to the progression or death, due to any cause, up to 24 months. patient who does not progresses neither dies, is censored at the last tumor evaluation where no progression is detected.]. Median, Months (95% Confidence Interval). Integrase Inhibitors: Experimental Arm (n=20): 2.5 (1.4 to 9.6). No Integrase Inhibitors: Experimental Arm (n=20): 2.5 (0.4 to 6.2).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

PFS Analysis by Dolutegravir [From the inclusion date to the progression or death, due to any cause, assessed up to 24 months.]. Median, Month (95% Confidence Interval). Dolutegravir: Experimental Arm (n=20): 4.2 (1.0 to 17.0). No Dolutegravir: Experimental Arm (n=20): 2.3 (0.4 to 4.1).